InvestorWire NewsRoom

InvestorNewsBreaks

NewsBreak Category: Biotechnology
Friday Mar 15, 2024 - 1:53 pm

InvestorNewsBreaks – Astiva Health Addressing Challenges of Traditional Caregiving Structures

Astiva Health is a leading healthcare provider that specializes in delivering personalized and comprehensive solutions to diverse communities. The company is leading the charge in creating essential healthcare solutions tailored for the expanding aging Asian American community, which is undergoing a considerable demographic shift, with a growing segment of the population requiring more support. “The company is proactively meeting the unique needs of this group…

Continue Reading

Friday Mar 15, 2024 - 1:11 pm

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Filling Gap in Therapeutic Antibody Treatment Space

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, is currently focused on the development of four therapeutic candidates to address clearly defined limitations in global health. These include the ImmunePrep(TM) platform to enhance the performance of immunotherapeutic antibodies to treat cancer, ChemoPrep(TM) to enhance the targeted delivery of chemotherapy, ChemoPure(TM) to reduce the toxicity of chemotherapy, and Sigyn Therapy(TM) to address pathogen-associated conditions that…

Continue Reading

Friday Mar 15, 2024 - 10:34 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Publication of Peer-Reviewed Research for Investigational Drug CNM-Au8(R)

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced the publication of peer-reviewed research, titled “Protein Corona Composition of Gold Nanocrystals.” The publication appeared in the journal ACS Pharmacology & Translational Science and fully characterized the proteins from human…

Continue Reading

Friday Mar 15, 2024 - 9:35 am

InvestorNewsBreaks – Cognition Therapeutics Inc. (NASDAQ: CGTX) Closes on $11.5M Public Offering

Cognition Therapeutics (NASDAQ: CGTX), a clinical-stage company developing product candidates designed to treat neurodegenerative disorders, has closed on its previously announced underwritten public offering. The offering was comprised of 6,571,428 shares of its common stock. According to the announcement, each share of common stock was sold at $1.75 per share, resulting in approximately $11.5 million in gross proceeds before deductions, commissions and expenses. Cognition Therapeutics…

Continue Reading

Thursday Mar 14, 2024 - 2:31 pm

InvestorNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT) Announces Highly Promising Results from ODF Cladribine PK Study

BioNxt (CSE: BNXT) (OTCQB: BNXTF) (FSE: BXT) has announced completion of the comparative pharmacokinetic (“PK”) study for its oral dissolvable film (“ODF”) based proprietary Cladribine product for the treatment of multiple sclerosis (“MS”). The company reported that the animal PK study results are highly promising and demonstrated comparable rapid absorption and systemic exposure between BioNxt’s ODF product and the name-brand reference drug in all samples.…

Continue Reading

Thursday Mar 14, 2024 - 12:00 pm

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Enrolls First Patients in Key Study Assessing Proprietary AIMIGo(TM) System

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has begun enrolling the first patients in its VALID-ECG pivotal study. According to the announcement, the first patients were enrolled at Atlanta Heart Specialists, a top cardiology physician practice in Atlanta, Georgia. HeartBeam anticipates the VALID-ECG study will form the basis of its planned FDA 510(k) submission.…

Continue Reading

Wednesday Mar 13, 2024 - 11:54 am

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Shares Vision, Innovations in ASD Treatments in Updated Company Presentation

PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. The comprehensive overview showcases PaxMedica’s strategic direction, recent advancements in autism spectrum disorder (“ASD”) therapeutics, and its commitment to addressing unmet needs within the ASD community. “PaxMedica is pleased to share our vision and progress with the wider community,” said Howard Weisman, chairman…

Continue Reading

Wednesday Mar 13, 2024 - 11:37 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces FY 2023 Results, Recent Operating Highlights

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced its full year 2023 financial results. In addition, the company provided recent operating highlights for the clinical programs in amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). “In 2024 we…

Continue Reading

Tuesday Mar 12, 2024 - 12:47 pm

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Showcasing Services, Meeting with Investors at Upcoming BIO-Europe Spring 2024

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing CDMO services through its Scinai Bioservices business unit, will be participating at this month’s BIO-Europe Spring 2024 conference. The conference is scheduled for March 18–20, 2024, in Barcelona. According to the announcement, Scinai management will be attending the event and will be available for discussions with…

Continue Reading

Monday Mar 11, 2024 - 10:43 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Takes First Step Toward Obtaining Permission for unbuzzd(TM) Phase-1b Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a Clinical Trial Application (“CTA”) for its planned phase-1b clinical trial. According to the announcement, the trial will focus on evaluating the safety and efficacy of unbuzzd(TM) in healthy volunteers in an induced state of…

Continue Reading

Friday Mar 08, 2024 - 2:33 pm

InvestorNewsBreaks – Astrotech Corporation’s (NASDAQ: ASTC) Subsidiary Tapping into Fast-Growing Opportunity

Astrotech (NASDAQ: ASTC), a science and technology company focused on commercializing its innovative platform mass spectrometry technology through its wholly owned subsidiaries, recently released financial results for Q2 2024. “The company recorded a 512% jump in its year-to-date (‘YTD’) revenue to $1,540,000 from $301,000 in the comparative period a year before. Astrotech attributed this growth primarily to two significant purchase orders for the TRACER 1000(TM)…

Continue Reading

Friday Mar 08, 2024 - 1:03 pm

InvestorNewsBreaks – Astiva Health Redefining Personalized and Comprehensive Healthcare Standards

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive healthcare solutions to diverse communities, is carving out a niche as a rapidly growing Medicare Advantage Prescription Drug (“MAPD”) health plan in a landscape where more individuals are becoming eligible for Medicare. “Astiva stands out by redefining personalized and comprehensive healthcare standards… Astiva is redefining healthcare standards by improving member services, medical…

Continue Reading

Thursday Mar 07, 2024 - 12:17 pm

InvestorNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Awarded Two New US Patents Covering Core Cardiac Monitoring Technology

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has received notification that two of its patents covering core vectorelectrocardiography (“VECG”) have been awarded by the United States Patent and Trademark Office. The two new patents bring the total of issued patents in HeartBeam’s portfolio to 14, with four international patents as well; the company also…

Continue Reading

Thursday Mar 07, 2024 - 9:51 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Participation at Upcoming 36th Annual Roth Conference

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., will be represented at this month’s annual Roth Conference. The conference will be held March 18–19, 2024, in Dana Point, California. According to the announcement, company officials are scheduled to present a fireside chat, slated to begin at 8 a.m. PST on March 18, 2024. Clene focuses on improving…

Continue Reading

Tuesday Mar 05, 2024 - 11:03 am

InvestorNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q4 and FY 2023 Results Call

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced that it will hold a conference call to discuss its results for the fourth quarter and full fiscal year ended Dec. 31, 2023. During the call, slated to begin at 4:30 p.m. ET on Wednesday, March 20, 2024, HeartBeam executives will also provide regulatory updates,…

Continue Reading

Tuesday Mar 05, 2024 - 10:49 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Presents Positive Results on First-in-Human Phase 1 Study of Lucid-MS

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, today announced its participation in Americas Committee for Treatment and Research in Multiple Sclerosis (“ACTRIMS”) 2024 Forum. Held during Feb. 29 - Mar 2, 2024, in West Palm Beach, Florida, the annual conference is the largest MS event of its kind in North…

Continue Reading

Monday Mar 04, 2024 - 1:35 pm

InvestorNewsBreaks – BioVie Inc. (NASDAQ: BIVI) to Secure ~$21M in Public Offering

BioVie (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders. The company today announced the pricing of its best efforts public offering of 21,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 10,500,000 shares of common stock at a combined offering price…

Continue Reading

Friday Mar 01, 2024 - 3:21 pm

InvestorNewsBreaks – Astrotech Corporation’s (NASDAQ: ASTC) Breakthrough TRACER 1000(TM) Designed to Outperform Currently Used IMS Detectors

Astrotech (NASDAQ: ASTC) is a mass spectrometry company that, through its wholly owned subsidiary 1st Detect, has developed and rolled out the breakthrough TRACER 1000(TM) Explosive Trace Detector (“ETD”). “The world’s first mass spectrometry-based ETD certified by the European Civil Aviation Conference (‘ECAC’), the TRACER 1000(TM) is designed to outperform the ETDs currently used at aviation checkpoints as well as borders, cargo facilities and other…

Continue Reading

Friday Mar 01, 2024 - 3:05 pm

InvestorNewsBreaks – Astiva Health Redefining the Standards of Personalized and Comprehensive Healthcare

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive solutions to diverse communities, is one of the companies committed to providing robust and stable benefit offerings to a growing number of people looking for the best Medicare options. “In a space where a growing number of individuals are qualifying for Medicare, Astiva Health is differentiating itself as a fast-growing Medicare Advantage…

Continue Reading

Friday Mar 01, 2024 - 2:06 pm

InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Committed to Developing Groundbreaking Therapies, Transformative Solutions

PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company is on a promising path to address unmet medical needs of ASD patients. “The prevalence of ASD in the United States has risen to approximately 1 in 36 children, according…

Continue Reading

Thursday Feb 29, 2024 - 12:12 pm

InvestorNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Planned Participation at MIXiii 2024, Bio Europe Spring Conference

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit, today announced that it will be attending the MIXiii International Life Science and Health-tech Conference. The event is slated to take place March 5 and 6 in Jerusalem. Several members of Scinai’s leadership team will be available for discussions…

Continue Reading

Thursday Feb 29, 2024 - 9:52 am

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN), Subsidiary Report Positive Clinical Results of CNM-Au8 Treatment at MS Forum

Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company, and its wholly owned subsidiary Clene Nanomedicine Inc., is reporting on the full clinical results for CNM-Au8(R), an investigational first-in-class therapy designed to improve central nervous system cells’ survival and function. Clene, which is focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), presented…

Continue Reading

Wednesday Feb 28, 2024 - 10:33 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Board of Directors Approves Debt Settlement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has announced a debt settlement. According to the announcement, the company’s board of directors approved the settlement of $637,650 owed to arm's length creditors through issuing 545,000 Class B subordinate voting shares in the capital of the corporation; the shares were issued at…

Continue Reading

Wednesday Feb 28, 2024 - 9:00 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Reports on Year-End 2023 Financial Results, Corporate Update

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has released a financial report for the year ended Dec. 31, 2023; the report also included a corporate update. The report noted that revenues for 2023 totaled $0.7 million with grant revenue for 2023 being less than $0.1 million; related cost of revenues was $0.5 million for 2023; and gross profit…

Continue Reading

Tuesday Feb 27, 2024 - 3:09 pm

InvestorNewsBreaks – Clene Inc.’s (NASDAQ: CLNN) CNM-Au8 Aiming to Address Neurodegenerative Diseases from a New Angle

Clene (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s and multiple sclerosis (“MS”). “The company’s lead drug candidate is CNM-Au8, an innovative nanomedicine uniting the principles of physics, chemistry, materials science, and biology to address neurodegenerative diseases from a new angle. Clene uses catalytic boosting of…

Continue Reading

Monday Feb 26, 2024 - 11:41 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), Subsidiary Enter Agreement for Clinical Trial of Proprietary Blend Beverage

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, and its subsidiary, HUGE Biopharma Australia Pty Ltd., have entered into an agreement with Ingenu CRO Pty Ltd. The agreement outlines a study to assess the safety and efficacy of unbuzzd(TM), a fortified oral liquid formula, being used as a treatment with healthy…

Continue Reading

Thursday Feb 22, 2024 - 12:45 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Announces Statistically Significant Results from Independent Analyses of ALS Patient Data

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today reported new, significant survival results in amyotrophic lateral sclerosis (“ALS”) patients. According to the announcement, the results are from two independent analyses of pooled data from two intermediate-size “Companionate Use” Expanded…

Continue Reading

Thursday Feb 22, 2024 - 9:21 am

InvestorNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Announces Plans to Release Year-End 2023 Financial Results, Corporate Update

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has scheduled a conference call to discuss its financial results for 2023. The company announced that it will release its 2023 financial results after market close on Feb. 27, 2024, and will host a conference call at 5 p.m. ET that same day. During the call, company officials will provide an…

Continue Reading

Wednesday Feb 21, 2024 - 3:11 pm

InvestorNewsBreaks – Astrotech Corporation’s (NASDAQ: ASTC) Subsidiary Bringing ‘Game Changer’ Technology in AgLAB MVP

Astrotech’s (NASDAQ: ASTC) subsidiary AgLAB, Inc. has breakthrough mass spectrometry technology in its AgLAB 1000-D2 mass spectrometer and the Maximum Value Process(TM) testing method (“AgLAB MVP”). “AgLAB MVP is designed to improve yields and bottom-line profits for hemp (‘CBD’) and cannabis (‘THC’) producers of CBD-THC oils by up to 30%. Large-scale CBD and THC oil processors use molecular distillation systems (‘MDS’) to produce the valuable…

Continue Reading

Wednesday Feb 21, 2024 - 2:07 pm

InvestorNewsBreaks – Longeveron Inc.’s (NASDAQ: LGVN) ELPIS Trial Demonstrates Potential Survival Benefit of Lomecel-B(TM) for HLHS Patients

Longeveron’s (NASDAQ: LGVN) extended long-term follow-up data from the ELPIS I study was presented as a poster at the annual Scientific Sessions of the American Heart Association (“AHA”). “ELPIS I was designed to assess the safety and potential efficacy of intramyocardial injection of Lomecel-B(TM) administered to 10 infants with hypoplastic left heart syndrome (‘HLHS’) during Stage II surgeries at approximately 4 months of age. The…

Continue Reading

Wednesday Feb 21, 2024 - 1:19 pm

InvestorNewsBreaks – Modular Medical Inc. (NASDAQ: MODD) Announces Pricing of $10M Public Offering

Modular Medical (NASDAQ: MODD), a development-stage insulin delivery technology company seeking to launch the next generation of easy-to-use and affordable insulin pump technology, previously announced the pricing of its underwritten public offering of 9,090,910 shares of its common stock. The offering is led by Manchester Explorer, L.P., which is managed by Jeb Besser, Modular Medical’s chief executive officer, Morgan Frank, a member of the company’s…

Continue Reading

Tuesday Feb 20, 2024 - 3:13 pm

InvestorNewsBreaks – Clene Inc. (NASDAQ: CLNN) Eyes ‘Rarely Seen’ Clinically Significant Improvement in MS Patients

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, recently reported new results from a long-term open-label extension (“LTE”) of the VISIONARY-MS trial in participants with stable relapsing multiple sclerosis (“RMS”) totaling nearly three years of follow up. Data from the study show clear overall improvements…

Continue Reading

Tuesday Feb 20, 2024 - 10:27 am

InvestorNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters Market Offering Agreement

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into an agreement. The market offering agreement is with H.C. Wainwright & Co. LLC. According to the agreement, FSD Pharma may offer and sell Class B subordinate voting shares in the capital of the company at its discretion. The offering may…

Continue Reading

Tuesday Feb 20, 2024 - 9:45 am

InvestorNewsBreaks — Astiva Health Opens Doors to New LA-Koreatown Activity Center, Marks ‘Testament’ to Empowering Seniors

Astiva Health, a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan dedicated to reshaping personalized and comprehensive healthcare, has opened a new facility in Los Angeles. The company is celebrating the Dec. 16, 2023, opening of its Los Angeles-Koreatown Activity Center. The grand-opening ceremony, which marked a milestone for Astiva in its efforts to serve the senior community of Koreatown, included a ribbon cutting by…

Continue Reading

Thursday Feb 15, 2024 - 1:43 pm

InvestorNewsBreaks – Datasea Inc. (NASDAQ: DTSS) Collaborates to Bring Unique Platform to New Customers

Datasea (NASDAQ: DTSS) is a Nevada incorporated digital technology corporation engaged in innovative business segments for intelligent acoustics and 5G multimodal communication technology in China. The company has announced that on Feb. 2, 2024, Guozhong Times (Beijing) Technology Ltd., a subsidiary of the Chinese operating company contractually controlled by Datasea, has entered into a cooperation agreement with Hangzhou Chongda Technology Co., Ltd. (“Chongda”) to increase…

Continue Reading

Wednesday Feb 14, 2024 - 9:48 am

InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Financial Numbers for Q2 2024, Corporate Update

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, is reporting on its financial results for Q2 2024, the period ended Dec. 31, 2023. The company also provided a corporate update, including plans to advance two preclinical programs in Alzheimer's and age-related macular degeneration. Highlights of the report included that the company closed the 2023…

Continue Reading

Tuesday Feb 13, 2024 - 12:34 pm

InvestorNewsBreaks – Renovaro Inc. (NASDAQ: RENB) Fusing AI and Biotech to Accelerate Personalized Medicine, GEDiCube, Cyclomics Enter LOI to ‘Change the Field’

Renovaro (NASDAQ: RENB) today announced the completion of its acquisition of GEDi Cube Intl Ltd. (“GEDiCube”). Renovaro, which means renew, combines the power of the AI Health Tech platform of GEDiCube with the advanced cell and gene-therapy Biotech platform of Renovaro Biosciences to accelerate precision, personalized medicine, marking a new era in healthcare innovation. According to the announcement, the two subsidiaries will be under the…

Continue Reading

Tuesday Feb 13, 2024 - 9:39 am

InvestorNewsBreaks – Astrotech Corp. (NASDAQ: ASTC) Releases Q2 2024 Financial Report

Astrotech (NASDAQ: ASTC), an innovative science and technology company, is releasing its financial results for Q2 2024, the period ended Dec. 31, 2023. Highlights of the report include a 512% increase in year-to-date revenue, which reached $1,540,000 compared to $301,000 in the same period in 2023; a strong consolidated balance sheet with $37 million in cash and liquid investments; and a year-to-date FY 2024 gross margin…

Continue Reading

Monday Feb 12, 2024 - 2:52 pm

InvestorNewsBreaks — Astiva Health Marks Pivotal Phase in Transforming Healthcare Delivery

Astiva Health, a leading healthcare provider that specializes in delivering personalized and comprehensive solutions to diverse communities, was spotlighted as a significant player in the Medicare Advantage Prescription Drug (“MAPD”) sector in a recent episode of the Bell2Bell Podcast. “The episode featured an exclusive interview with Astiva Health’s Co-Founder and CEO Dr. Tri Nguyen, a renowned expert in internal medicine and cardiology. During the interview,…

Continue Reading

Friday Feb 09, 2024 - 2:58 pm

InvestorNewsBreaks — Immix Biopharma Inc. (NASDAQ: IMMX) Closes on $15M Public Offering

Immix Biopharma (NASDAQ: IMMX), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and immunology, has closed on its previously announced underwritten public offering. The offering consisted of 5,535,055 shares of IMMX common stock, with each share sold at $2.71 per share. Gross proceeds from the offering to ImmixBio are projected to be an estimated $15 million, before standard deductions and expenses. According to the…

Continue Reading

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).